Get in Touch With Us
Revenue surged by 14% in Q1 FY25, reaching ₹458.64 crore, up from ₹403.46 crore in Q1 FY24.
EBITDA nearly doubled, growing by 93% to ₹55.05 crore compared to ₹28.51 crore in the same quarter last year.
Profit After Tax (PAT) jumped 147%, standing at ₹36.17 crore for Q1 FY25, up from ₹14.63 crore in Q1 FY24.
Morepen successfully raised ₹200 crore by Qualified Institutional Placement (QIP), oversubscribed by 1.68 times.
The pharma segment showed an 11% YoY growth with export revenue soaring by 32%, driven by strong performance in Europe and Asia.
Medical Devices revenue grew by 20%, with glucometer sales increasing by 17% and BP monitors growing by 29% YoY.
Revenue surged by 14% in Q1 FY25, reaching ₹458.64 crore, up from ₹403.46 crore in Q1 FY24.
EBITDA nearly doubled, growing by 93% to ₹55.05 crore compared to ₹28.51 crore in the same quarter last year.
Profit After Tax (PAT) jumped 147%, standing at ₹36.17 crore for Q1 FY25, up from ₹14.63 crore in Q1 FY24.
Morepen successfully raised ₹200 crore through Qualified Institutional Placement (QIP), oversubscribed by 1.68 times.
The pharma segment showed an 11% YoY growth with export revenue soaring by 32%, driven by strong performance in Europe and Asia.
Medical Devices revenue grew by 20%, with glucometer sales increasing by 17% and BP monitors
Empowering Health. Everywhere
Morepen is dedicated to providing affordable, high-quality healthcare solutions through innovative pharmaceutical and medical technology products. We strive to make health accessible for all and achieve a global reach.
Excellence. Passion. Action. Innovation
Morepen is driven by a commitment to excellence in everything we do. Our three core values – Passion, Action, and Innovation – guide our actions. We prioritize delivering superior quality products, efficient distribution networks, and exceptional customer service. We are a passionate and results-oriented team, leveraging technology for continuous research and development. Our goal is to remain at the forefront of healthcare solutions.
Annual Return
Annual Secretarial Compliance Report
Newspaper Advertisements
IT Policy
Investor Earning Call Q2 FY 2025
